Business Context and Reporting Period
This Form 8-K is filed by Aquestive Therapeutics, Inc. (AQST) on February 2, 2026, reporting events occurring on January 30, 2026. The filing primarily addresses regulatory developments regarding the Company's lead product candidate, Anaphylm (dibutepinephrine) Sublingual Film, intended for the treatment of Type I allergic reactions and anaphylaxis in patients weighing 30kg or more.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory status and strategic updates rather than financial performance data.
Material Changes and Regulatory Status
- FDA Complete Response Letter (CRL): The Company received a CRL from the U.S. FDA on January 30, 2026, for its New Drug Application (NDA) for Anaphylm.
- Nature of Deficiencies: The deficiencies cited in the CRL were limited to packaging and administration issues.
- Resubmission Timeline: Management believes these deficiencies can be rapidly resolved and expects to resubmit the NDA as early as the third quarter of 2026.
- Global Expansion: The Company initiated regulatory engagement in Canada, Europe, and the United Kingdom in 2025 and plans to seek regulatory approval in Canada and Europe in 2026.
Guidance, Outlook, and Risks
Management's outlook indicates confidence in resolving the FDA deficiencies quickly, targeting a Q3 2026 resubmission. The Company is actively advancing its global strategy with planned regulatory submissions in international markets later in 2026. The primary risk identified is the delay in U.S. market approval due to the CRL, though the Company characterizes the issues as non-clinical and resolvable. The filing also notes that the investor presentation attached as Exhibit 99.2 contains forward-looking information that may be amended or updated.
Investor Verification Checklist
- Verify the specific details of the packaging and administration deficiencies in the attached FDA CRL (Exhibit 99.1).
- Confirm the timeline for the resubmission of the NDA in Q3 2026.
- Review the status of regulatory engagements in Canada, Europe, and the UK as detailed in the investor presentation (Exhibit 99.2).
- Monitor subsequent filings for updates on the resubmission date and any changes to the global approval strategy.